Intellia Therapeutics’ Lonvo-z Shows Promising Efficacy and Safety, Supporting Buy Rating

Intellia Therapeutics (NTLA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on the stock and has a $20.00 price target.

Kostas Biliouris has given his Buy rating due to a combination of factors surrounding Intellia Therapeutics’ promising developments with their Lonvo-z treatment. The updated Phase I data for Lonvo-z (NTLA-2002) indicates a 100% attack-free rate in patients, which suggests a strong potential for curative outcomes in hereditary angioedema (HAE). This impressive efficacy, particularly in patients receiving the registrational dose, underscores the treatment’s potential success in future phases and its attractiveness to patients seeking a single-course curative option.
Furthermore, the safety profile of Lonvo-z remains favorable, with no significant adverse effects reported. The anticipated Phase II data in the latter half of the year could further solidify Lonvo-z’s competitive position ahead of its Phase III readout. Additionally, the resolution of uncertainties regarding IND approval in the U.S. and the minimal expected impact of CRISPR/Cas9 IP litigations contribute to a positive outlook for Intellia Therapeutics. These elements collectively support the Buy rating, highlighting the company’s potential for growth and success in the therapeutic market.

According to TipRanks, Biliouris is an analyst with an average return of -14.9% and a 32.64% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Crispr Therapeutics AG, and Legend Biotech.

In another report released today, Wells Fargo also maintained a Buy rating on the stock with a $50.00 price target.